Alberto Lázaro-García
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alberto Lázaro-García has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Edwin Uriel Suárez
Department of Hematology, Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid, Madrid, Spain
2 shared publications Carlos Lacalle-Gonzalez
Department of Medical Oncology, Fundación Jiménez Díaz University Hospital, Madrid, Spain
1 shared publicationCarlos Santonja
Department of Pathology, Fundacion Jimenez Diaz University Hospital, Madrid, Spain
1 shared publicationCarlos Soto
Department of Haematology Fundación Jiménez Díaz University Hospital Madrid Spain
1 shared publication- Daniel Láinez-González
Experimental Hematology, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Avenida Reyes Católicos 2, 28040 Madrid, Spain
1 shared publication Daniel Morillo
Department of Hematology and Hemotherapy, Fundación Jiménez Díaz University Hospital, Madrid, Spain
1 shared publication
Latest Publications
- 4 March 2024
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 67 (6)
Music Listening in Stem Cell Transplantation and Acute Myeloid Leukemia: A Randomized Clinical Trial
- 4 March 2024
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 67 (6)
Music Listening in Stem Cell Transplantation and Acute Myeloid Leukemia: A Randomized Clinical Trial
- 10 March 2022
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 44 (4) , e172-e174
Search for the cause of anaemia and neutropenia in a patient with well‐controlled systemic lupus erythematosus
- 10 March 2022
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 44 (4) , e172-e174
Search for the cause of anaemia and neutropenia in a patient with well‐controlled systemic lupus erythematosus
- Open Access
- 1 March 2022
- Published by Taylor & Francis in Hematology
- Vol. 27 (1) , 318-321
A journey through anticoagulant therapies in the treatment of left ventricular thrombus in post-COVID-19 heparin-induced thrombocytopenia: a case report
Heparin-induced thrombocytopenia (HIT) is an immune-mediated adverse drug reaction associated with thrombosis. Clinical scoring systems and the presence of anti-platelet factor 4 (anti-PF4)/heparin antibodies determine the diagnosis. A 57-year-old man who was treated with acenocoumarol due to a chronic left ventricular thrombus was admitted to the hospital for severe SARS-CoV-2 pneumonia and pulmonary embolism. The patient was started on bemiparin and discharged. Left lower limb acute arterial ischemia and thrombocytopenia were diagnosed 18 days later. Computed tomography angiography revealed a large left ventricular thrombus and multiple arterial thrombi. Left femoral-popliteal thromboembolectomy was performed. Anti-PF4/heparin antibodies confirmed an HIT diagnosis. Fondaparinux (7.5 mg/24 h) was initiated, but cardiac surgery was necessary. Bivalirudin was used during surgery, with an initial load (1.25 mg/kg) and maintenance infusion (2.5 mg/kg/h). The cardiac thrombus was extracted, but the patient experienced a postsurgical myocardial infarction. Percutaneous cardiovascular intervention (PCI) required a bivalirudin load (0.75 mg/kg) and maintenance infusion (1.75 mg/kg/h). No coronary lesions were detected, and argatroban was started afterwards (0.5 µg/kg/min). When the platelet count exceeded 100 × 109/L, acenocoumarol was initiated. Thereupon, acetylsalicylic acid (100 mg/24 h) was added. No other complications have been reported to date. The clinical presentation of intraventricular and multiple arterial thrombi is remarkable. SARS-CoV-2 infection likely contributed to a hypercoagulable state. The management of patients with HIT undergoing cardiac surgery is challenging. If surgery cannot be delayed, then treatment with bivalirudin is recommended. Additionally, this drug is recommended for PCI. Bivalirudin is safe and well-tolerated in both procedures.
- 1 March 2022
- Published by Taylor & Francis in Hematology
- Vol. 27 (1) , 318-321
Open AccessA journey through anticoagulant therapies in the treatment of left ventricular thrombus in post-COVID-19 heparin-induced thrombocytopenia: a case report
Heparin-induced thrombocytopenia (HIT) is an immune-mediated adverse drug reaction associated with thrombosis. Clinical scoring systems and the presence of anti-platelet factor 4 (anti-PF4)/heparin antibodies determine the diagnosis. A 57-year-old man who was treated with acenocoumarol due to a chronic left ventricular thrombus was admitted to the hospital for severe SARS-CoV-2 pneumonia and pulmonary embolism. The patient was started on bemiparin and discharged. Left lower limb acute arterial ischemia and thrombocytopenia were diagnosed 18 days later. Computed tomography angiography revealed a large left ventricular thrombus and multiple arterial thrombi. Left femoral-popliteal thromboembolectomy was performed. Anti-PF4/heparin antibodies confirmed an HIT diagnosis. Fondaparinux (7.5 mg/24 h) was initiated, but cardiac surgery was necessary. Bivalirudin was used during surgery, with an initial load (1.25 mg/kg) and maintenance infusion (2.5 mg/kg/h). The cardiac thrombus was extracted, but the patient experienced a postsurgical myocardial infarction. Percutaneous cardiovascular intervention (PCI) required a bivalirudin load (0.75 mg/kg) and maintenance infusion (1.75 mg/kg/h). No coronary lesions were detected, and argatroban was started afterwards (0.5 µg/kg/min). When the platelet count exceeded 100 × 109/L, acenocoumarol was initiated. Thereupon, acetylsalicylic acid (100 mg/24 h) was added. No other complications have been reported to date. The clinical presentation of intraventricular and multiple arterial thrombi is remarkable. SARS-CoV-2 infection likely contributed to a hypercoagulable state. The management of patients with HIT undergoing cardiac surgery is challenging. If surgery cannot be delayed, then treatment with bivalirudin is recommended. Additionally, this drug is recommended for PCI. Bivalirudin is safe and well-tolerated in both procedures.
- 17 March 2021
- Published by S. Karger AG in Oncology Research and Treatment
- Vol. 44 (4) , 196-200
Post-Chemotherapy Rebound Thymic Hyperplasia Mimicking Relapse in Breast Implant-Associated Anaplastic Large Cell Lymphoma: A Case Report
Introduction: Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an unusual form of T-cell non-Hodgkin lymphoma. Surgical management is essential; however, adjuvant therapy is recommended for advanced stages of cancer. Case Presentation: A 40-year-old woman with textured silicone implants placed 7 years earlier, presented with breast nodules. Physical examination and computed tomography (CT) revealed a left parasternal mass, 2 left-breast nodules, and axillary lymphadenopathies. A soft-tissue lesion in the anterior mediastinum consistent with thymic remnants was detected. BIA-ALCL was diagnosed based on ultrasound-guided core biopsies of an axillary lymph node and a breast nodule. She underwent total bilateral capsulectomy and received anthracycline-based adjuvant chemotherapy. End-of-treatment positron emission tomography-computed tomography (PET-CT) scan at 4 months showed no evidence of disease, except for the persistence of the mediastinal lesion (Deauville score 4). Three months later, a new PET-CT scan showed enlargement of the lesion and increased radiotracer uptake, suggesting metabolic progression. A mediastinal biopsy was performed and rebound thymic hyperplasia (RTH) was observed in the histopathologic study. Once complete remission (CR) was achieved, the patient was followed up continually and has shown no signs of relapse to date. Conclusions: Further studies are required to determine the best adjuvant therapy for advanced BIA-ALCL. RTH may be suspected when thymic enlargement without the involvement of other areas is observed in patients with cancer. Mediastinal biopsy is mandatory to rule out relapse.
- 17 March 2021
- Published by S. Karger AG in Oncology Research and Treatment
- Vol. 44 (4) , 196-200
Post-Chemotherapy Rebound Thymic Hyperplasia Mimicking Relapse in Breast Implant-Associated Anaplastic Large Cell Lymphoma: A Case Report
Introduction: Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an unusual form of T-cell non-Hodgkin lymphoma. Surgical management is essential; however, adjuvant therapy is recommended for advanced stages of cancer. Case Presentation: A 40-year-old woman with textured silicone implants placed 7 years earlier, presented with breast nodules. Physical examination and computed tomography (CT) revealed a left parasternal mass, 2 left-breast nodules, and axillary lymphadenopathies. A soft-tissue lesion in the anterior mediastinum consistent with thymic remnants was detected. BIA-ALCL was diagnosed based on ultrasound-guided core biopsies of an axillary lymph node and a breast nodule. She underwent total bilateral capsulectomy and received anthracycline-based adjuvant chemotherapy. End-of-treatment positron emission tomography-computed tomography (PET-CT) scan at 4 months showed no evidence of disease, except for the persistence of the mediastinal lesion (Deauville score 4). Three months later, a new PET-CT scan showed enlargement of the lesion and increased radiotracer uptake, suggesting metabolic progression. A mediastinal biopsy was performed and rebound thymic hyperplasia (RTH) was observed in the histopathologic study. Once complete remission (CR) was achieved, the patient was followed up continually and has shown no signs of relapse to date. Conclusions: Further studies are required to determine the best adjuvant therapy for advanced BIA-ALCL. RTH may be suspected when thymic enlargement without the involvement of other areas is observed in patients with cancer. Mediastinal biopsy is mandatory to rule out relapse.